BLAINJECTIONSOLUTIONPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
32
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 20h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (32)
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
Started Apr 2026
160 enrolled
Multiple MyelomaNewly Diagnosed Multiple MyelomaTransplant Ineligible+1 more
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Started Mar 2026
34 enrolled
Phase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more
A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan
Started Mar 2026
30 enrolled
Refractory Multiple Myeloma (RRMM)
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Started Feb 2026
26 enrolled
Multiple Myeloma
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
Started Dec 2025
159 enrolled
TCE-RRMM
Worked on ELREXFIO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.